A 38-year-old woman presents to the emergency department on day 3 of acute onset fever (39.5°C), cough, myalgia, and headache. She is otherwise healthy with no comorbidities. Rapid influenza diagnostic test (RIDT) is positive for influenza A. Chest X-ray shows no infiltrates. Oxygen saturation is 96% on room air. What is the most appropriate next step in management?

Explanation

## Clinical Context This is an uncomplicated influenza A infection in an immunocompetent adult presenting within 48 hours of symptom onset, with no signs of severe disease (normal oxygen saturation, no pneumonia on imaging). ## Management Approach for Uncomplicated Influenza **Key Point:** Antiviral therapy (neuraminidase inhibitors) is most effective when started within 48 hours of symptom onset and should be initiated immediately upon diagnosis in symptomatic patients, regardless of RIDT sensitivity. **High-Yield:** In uncomplicated influenza without severe disease or risk factors, oral oseltamivir is first-line. Treatment reduces symptom duration by ~1 day and prevents complications in high-risk groups. ## Why Oseltamivir Now? 1. **Timing is critical:** Day 3 of illness is still within the 48-hour window for maximum antiviral benefit 2. **RIDT is sufficient:** Positive RIDT in a symptomatic patient is adequate to initiate therapy; RT-PCR confirmation is not required before starting antivirals 3. **No severe disease:** No hypoxemia, no pneumonia, no comorbidities → outpatient oral therapy is appropriate 4. **Symptomatic benefit:** Early oseltamivir reduces fever duration and symptom severity **Clinical Pearl:** The key decision point is whether the patient has severe disease, complications, or risk factors (age >65, pregnancy, chronic cardiopulmonary disease, immunosuppression). This patient has none, so oral outpatient therapy is safe and effective. ## Dosing Oseltamivir: 75 mg PO BID × 5 days (standard adult dose) [cite:Harrison 21e Ch 195]